La cadena de opciones muestra datos clave de las opciones de acciones de Enzolytics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Enzolytics..

Enzolytics (OTC:ENZC) Bolsa, Cadena de Opciones

Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize HIV.

Enzolytics Inc

News

Offerings

CSWC

Capital Southwest Corp Files For Common Stock Offering Of Up To $1B

Southwest Gas Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) ("Southwest Gas Holdings" or the "Company") today announced the commencement of an underwritten secondary public offering of Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri") common stock (the "Offering"), pursuant to which Southwest Gas Holdings, as the selling stockholder, is offering 9,000,000 existing shares of Centuri's common stock. Southwest Gas Holdings expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Centuri's common stock.
In addition to the shares of Centuri's common stock sold in the Offering, Southwest Gas Holdings announced that Icahn Partners and Icahn Partners Master Fund LP, investment entities affiliated with&nbsp;Carl C. Icahn, will purchase an aggregate of&nbsp;$50 million in shares of&nbsp;Centuri's common stock from Southwest Gas Holdings in a concurrent private placement at a price per share equal to the Offering price per share. The concurrent private placement is expected to close immediately following the closing of the Offering and is subject to the satisfaction or waiver of customary closing conditions, including the completion of the Offering. The sale of these shares will not be registered under the Securities Act of 1933, as amended (the "Securities Act"). The closing of the Offering is not conditioned upon the closing of the concurrent private placement.

CTRI

Southwest Gas Holdings Launches Secondary Public Offering Of 9M Centuri Shares And Announces $50M Private Placement With Icahn Affiliates At Offering Price

WIIM

D.R. Horton shares are trading higher in possible sympathy with Toll Brothers, which rose after reporting Q2 results.

I got into the investment business on a steady diet of Graham and Whitman. But that was the 1980s and early 1990s – the golden age of dealmakers and junk bonds, leveraged buyouts and greenmail. 
Long before the players became gentlemanly private equity titans and activist investors, they were raiders, vultures, and even, in one famous book about the RJR deal, barbarians.
Legendary fortunes were made, reputations created and shattered.
All of these high-return, high-flying strategies shared a common thread. Leveraged buyouts, distressed investing and risk arb were all just variations on the value investing theme.
The private equity giants of today are still doing this. Thanks to their quarterly filings, you can copy their investment approach—a strategy that has beaten the markets 4-to-1 since 2001.
Even the creation of the junk bond market was based on Michael Milken&#8217;s studies on the returns from buying undervalued lower-rated bonds, a strategy founded on basic value investing principles.
The big winners in all these strategies took value investing and added debt.
It was like adding nitro to the tank of a stock car. If you could control the vehicle at high speed through the corners, there was no race you couldn&#8217;t win.
Although the golden age of risk arb and the smaller investors&#8217; ability to compete in distressed debt are all behind us, we can still use the combination of debt and value investing to beat the index by a wide margin.
When the 13F filings come out every quarter, most of the short-attention-spans in the market today head for the same filings at the same time.
Warren, Cathie, Stanley, Tepper and Seth still get all the attention.
I may get around to those at some point, but one of the first places I turn is to the leading private equity firms.
Firms like Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) and KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) still use basic principles of value investing along with a healthy dose of debt to drive massive returns for themselves and their investors.
What most people do not realize is that these firms also have large public securities portfolios, and stealing their ideas has created some massive market-beating opportunities.
If you had bought shares of Mr. Cooper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) when it first appeared in KKR&#8217;s public portfolio in 2018, you could have made almost ten times your money.
Buying shares of AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) when KKR first revealed its position would have resulted in gains of almost seven times your initial cost.
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) would have delivered gains of 3x in just a few years.
Owning the firm&#8217;s top ten holdings since 2001 would have beaten the market by a 4-to-1 margin.
I do not care what the media darling investors bought last quarter. Tell me what the profit pirates at KKR own, and I can create an opportunity to score massive gains.
The current top ten holdings for KKR are:
BrightSpring Health Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) provides home and community-based health services to complex patients, positioning itself in a niche with long-term demographic tailwinds. The company is newly public and pursuing scale through both organic growth and targeted acquisitions in behavioral and specialty pharmacy segments.
Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is a global distributor of dental and medical supplies primarily serving small- and mid-sized practices. The company generates stable cash flow and has a long history of disciplined capital deployment, though growth is modest and sensitive to procedure volume trends.
BrightView (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) is the largest commercial landscaping services provider in the U.S., with recurring maintenance revenue making up the majority of its business. Under new leadership, the firm is undergoing a restructuring push to improve margins and reduce debt after years of underperformance.
KKR Real Estate Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is a commercial mortgage REIT focused on senior loans backed by institutional-grade real estate, primarily in urban markets. It offers a high dividend yield but remains exposed to office market weakness and refinancing risk in a higher-rate environment.
Madison Square Garden Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) owns marquee sports franchises, including the New York Knicks and Rangers, offering investors a rare asset-backed play on professional sports. Valuation is driven more by franchise appreciation than earnings power, making it a long-duration, event-driven asset.
Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) is a leading cruise operator with a strong focus on premium and upscale offerings across its brand portfolio. The company is rebounding from pandemic-era disruptions, though it still carries significant leverage and remains sensitive to fuel and labor costs.
Bausch Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) is a diversified specialty pharmaceutical company with exposure to eye health, dermatology, and branded generics. However, the company is still burdened by high legacy debt. While it&#8217;s pursuing a turnaround strategy and asset divestitures, legal overhangs and weak cash flow remain headwinds.
FS KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is one of the largest business development companies, focused on senior secured lending to middle-market companies with an emphasis on downside protection. It offers a double-digit yield and strong sponsor backing, though credit quality and NAV stability require close monitoring.
Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGY#NYSE">CSGY</a>) is a cash-generating E&amp;P company with a private equity-backed structure and a focus on acquiring and optimizing mature, low-decline assets. The firm maintains a disciplined capital return framework and hedging strategy, making it a defensive upstream play with yield upside.
BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) is a commercial-stage biopharmaceutical company developing treatments for genetic diseases and cancers with clear genetic drivers. Its lead drug, Attruby (acoramidis), approved in late 2024 for transthyretin amyloid cardiomyopathy, significantly outperformed sales expectations in its first full quarter, positioning the company as a strong competitor in the cardiomyopathy treatment market.
<h2 class="wp-block-heading">Turn Market Mayhem Into Profit Signals This Memorial Day</h2>
Get real-time portfolio alerts, daily stock ideas, and a suite of pro-grade tools — all in one elite membership. For a limited time, you can access Benzinga Edge at 60% off. Secure Your 60% Memorial Day Discount <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-memorial-day-special/?utm_campaign=mdw-sale&amp;utm_adType=sponsorad&amp;utm_ad=RD052025/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">HERE</a>.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

BBIO

BTSG

COOP

CSGY

DASH

HSIC

KREF

MSGS

NCLH

The Smart Money Is Buying These 10 Stocks

KEYS

Keysight Technologies shares are trading higher following better-than-expected Q2 financial results.

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 15 years by 6.02% on an annualized basis producing an average annual return of 18.1%. Currently, TJX Companies has a market capitalization of $151.36 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 15 years ago, it would be worth $1,190.12 today based on a price of $134.64 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747773927_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In TJX Companies 15 Years Ago Would Be Worth This Much Today

DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes due 2033 (the "2033 notes"). The aggregate principal amount of the 2033 notes offered in the offering was increased from $750 million to $1 billion, and the 2033 notes were priced at 100.000% of their face amount to yield a 6.750% coupon. The offering is expected to close on May 23, 2025, subject to satisfaction of customary closing conditions.

DaVita Announces Upsize And Pricing Of Its Previously Announced Private Offering Of Its 6.750% Senior Notes Due 2033 From $750M To $1B

Earnings

Earnings Misses

EARN

Ellington Credit Q1 Adj. EPS $0.26 Misses $0.27 Estimate, Sales $9.25M Miss $9.35M Estimate

<h2 class="wp-block-heading">The request to get serious</h2>
Let's talk about exclusivity in M&amp;A transactions. The request for exclusivity often occurs at that moment in a deal where a buyer approaches a seller with the intention of making a commitment. "Hey, we want to buy you, but before we go too far down this road, we need to make sure you're not talking to anyone else." It's the financial equivalent of locking down a relationship: no swiping left or right while we're trying to make this work, okay?
Of course, in finance, nothing is ever that simple.
<h2 class="wp-block-heading">The exclusivity agreement</h2>
Let's say you're a company looking to get acquired, and you've been approached by a suitor. Maybe several, if you're lucky. Before the mayhem of the bidding war ensues, the buyer you like says, "We want a deal, but we need exclusivity for 45 days." Shorthand for, "We don't want you talking to anyone else while we're hammering out the details." Fair enough, right?
Here's the buyer's logic: Deals require lots of upfront investment in time and resources for due diligence, analysis on deal structuring etc. Buyers don't want to spend millions just to find out halfway through that you've been secretly talking to someone else and now you're going to pursue Option B instead.
<h2 class="wp-block-heading">Exclusivity's little twist: Is it really exclusive?</h2>
An exclusivity agreement sounds like it would be ironclad &#8211; no talking to other buyers, no shopping yourself around, nothing. You're locked in, right? Not quite. It's more like a promise that you won't actively seek out other deals. The door isn't totally locked – it's just slightly ajar. &nbsp;The company selling itself might still get unsolicited offers. If someone wants to slide a very tempting note under the door, technically no one is stopping them.
<h2 class="wp-block-heading">So, what happens when someone else knocks on your door?</h2>
What if, during your 45-day exclusivity window, another buyer shows up and waves a better deal in front of you? Now you're in a tough spot. Do you go back to your exclusive partner and say, "We've been offered something better. What can you do?"
You may be subject to a "no-shop" clause (i.e, you can't actively seek other offers), but you still need to protect yourself if an unsolicited offer presents a better opportunity. Ultimately, a seller's Board has a fiduciary duty to maximize value for its shareholders and must be cautious not to waive this obligation due to an exclusivity arrangement.
In other words, you can't shop yourself around, but if another buyer approaches you, well… your phone isn't exactly on airplane mode.
<h2 class="wp-block-heading">What if it all falls apart?</h2>
Let's say you've been in an exclusive process, hammering out details, and then the exclusivity period ends without a deal.&nbsp; This happened during Paramount's initial discussions with Skydance in mid-2024. Now, you're free to talk to other suitors like Paramount did with Apollo and Sony, yet there's no guarantee you'll get a better offer. Meanwhile, Skydance is still technically around (and may ultimately get to a signed deal), but the door is open for interlopers to engage in discussions.
The end of the exclusivity period gives you options, yet it also creates uncertainty. On the one hand, you can explore other opportunities, but on the other, new buyers may wonder why the last party didn't commit.
<h2 class="wp-block-heading">So, is exclusivity worth it?</h2>
It depends.
Here's where it gets tricky: exclusivity periods have been getting longer in recent years. In 2021, only 6% of deals had exclusivity periods longer than 60 days, but by 2022, that number increased to nearly 40%, a trend that is expected to continue (<a href="https://www.goodwinlaw.com/en/insights/publications/2023/05/insights-privateequity-ma-durations-exclusivity-periods?utm_source=chatgpt.com" target="_blank" rel="noreferrer noopener">Goodwin, 2023</a>).
So, while buyers prefer long exclusivity periods to facilitate comprehensive due diligence, sellers might be locking themselves into a deal that could ultimately fall apart. If exclusivity doesn&#8217;t result in a deal, a seller could spend months watching potential bidders fade away.
Exclusivity is often worth considering if:
<ol class="wp-block-list">
<li>The seller has a strong pre-existing relationship with a buyer</li>
<li>A buyer presents an exceptionally attractive offer (assuming they're serious)</li>
<li>The seller is in financial distress and exclusivity will facilitate a more rapid diligence timeline</li>
</ol>
Ultimately, agreeing to exclusivity with a buyer can be a double-edged sword. These decisions should always be made case-by-case, in consultation with financial advisors who can help evaluate the unique dynamics of each transaction.

Equities

Markets

Locked In: How Exclusivity Shapes the M&A Landscape

Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) released its second-quarter results after Tuesday's closing bell. Here's a look at the<a href="https://www.benzinga.com/pressreleases/25/05/b45529263/keysight-technologies-reports-second-quarter-2025-results"> details from the report. </a>
The Details: Keysight Technologies reported quarterly earnings of $1.70 per share, which beat the consensus estimate of $1.65. Quarterly revenue came in at $1.31 billion, which beat the Street estimate of $1.28 billion and is up from revenue of $1.22 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
<ul class="wp-block-list">
<li>Communications Solutions Group reported revenue of $913 million in the second quarter, up 9% from the prior year, reflecting 9% growth in commercial communications and 9% growth in aerospace, defense and government.</li>
<li>Electronic Industrial Solutions Group reported revenue of $393 million in the second quarter, up 5% from the prior year, reflecting growth in semiconductor and general electronics, partially offset by a decline in automotive and energy.</li>
</ul>
&#8220;Keysight delivered strong second quarter results with revenue and earnings per share above the high end of guidance. This quarter&#8217;s performance underscores the strength of our long-term strategy, deep customer engagement and disciplined execution,&#8221; said Satish Dhanasekaran, Keysight CEO.
&#8220;Even as we are monitoring the overall macroeconomic environment, we continue to see a healthy funnel of opportunities and are raising full-year growth expectations to the midpoint of our long-term 5%-7% target,&#8221; Dhanasekaran added.
Outlook:&nbsp;Keysight sees third-quarter EPS is a range of $1.63 to $1.69, versus the $1.69&nbsp;analyst estimate, and revenue of between $1.305 billion and $1.325 billion, versus the&nbsp;$1.3 billion&nbsp;estimate.
KEYS Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Keysight stock was up 4.60% at $170.28 after-hours Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Movers

Tech

Keysight Technologies Stock Climbs After Q2 Results: Here's Why

XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) reported quarterly losses of $(1.00) per share. This is a 66.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported $7.02 million in sales this quarter. This is a 19.52 percent decrease over sales of $8.73 million the same period last year.

XWEL

XWELL Q1 EPS $(1.00) Down From $(0.60) YoY, Sales $7.02M Down From $8.73M YoY

President Donald Trump has touted multi-trillion-dollar investment commitments as proof that his economic strategy is delivering a historic revival of <a href="https://www.benzinga.com/topic/donald-trump">American manufacturing and infrastructure. </a>
Yet, behind the massive figures, new analysis from Goldman Sachs suggests the actual economic impact could be far more modest.
Foreign governments and corporations have pledged over $6 trillion in U.S. investments, including $2 trillion from companies and $4.2 trillion from foreign governments, according to Goldman Sachs economist Joseph Briggs.
Just a week ago, President Trump secured $2 trillion in investment commitments from Gulf nations, including Saudi Arabia, Qatar and the United Arab Emirates. Meanwhile, Japan pledged $1 trillion.
Among the companies making the largest pledges, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) announced $787 billion, followed by International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with $409 billion, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with $302 billion, and Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with $35 billion.
"We expect the impact on U.S. investment to be smaller than suggested by these promises for three reasons," Briggs said in a report, highlighting project uncertainty, limited alignment with national accounts definitions, and overlap with prior plans.
<h3 class="wp-block-heading">The Real Investment Boost May Be Just $30B–$135B</h3>
After analyzing the announcements and stripping out less tangible commitments—like purchases of goods, partnerships, and reannounced projects—Goldman estimates that only $135 billion in new annual investment is directly tied to GDP-relevant projects like physical capital expenditures and R&amp;D. 
Applying historical realization rates and analyst feedback, the bank sees the likely net impact closer to $30 billion per year, or just 0.1% of U.S. GDP.
That figure starkly contrasts with headline projections that initially suggested a 4% GDP boost over time.
<h3 class="wp-block-heading">Why The Gap?</h3>
Many large-cap companies, including Apple Inc. and Nvidia Corp., have promised massive investments—$500 billion each over multiple years—but their past spending doesn't align. 
Apple spent just $10 billion on U.S. capex and $31.4 billion on global R&amp;D in 2024. Nvidia's corresponding figures were even lower, suggesting that headline figures may include spending on acquisitions, partnerships or input costs that don't translate into actual U.S. capital formation.
Further, Goldman's equity analysts found that 69% of the corporate investments likely overlap with previously planned spending, with just 6% seen as mostly new.
Goldman Sachs noted that &#8220;these announcements have not driven major upgrades to equity analyst capex forecasts.&#8221;
<h3 class="wp-block-heading">Foreign Deals May Help, If They Materialize</h3>
&#8220;In contrast to company-level announcements, investment promises from the United Arab Emirates, Saudi Arabia, Qatar, and Japan could provide a material incremental increase if they materialize,&#8221; Briggs said.
Countries like Saudi Arabia, Qatar, Japan and the UAE have announced ambitious commitments—from AI data centers to energy infrastructure and defense purchases.
Both Saudi Arabia and Qatar emphasized large-scale purchases of U.S. goods—$142 billion in defense contracts from Saudi Arabia and $96 billion in aircraft orders from Qatar—which would support U.S. GDP through exports, but not count as domestic investment. 
Yet, the lack of specificity on most other announced projects suggests that much of the foreign capital may contribute indirectly by lowering financing costs rather than driving immediate, measurable increases in U.S. capital formation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45528339/us-assets-still-vital-in-global-portfolios-despite-debt-downgrade-blackrock">US Assets Still Vital In Global Portfolios Despite Debt Downgrade: BlackRock </a></li>
</ul>
Photo: Shutterstock

Analyst Color

Large Cap

Politics

Econ #s

Analyst Ratings

AAPL

NVDA

Trump's $6 Trillion Investment Deals Face Reality Check: Only A Fraction May Reach The Real Economy

Daily Journal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJCO#NASDAQ">DJCO</a>) reported quarterly earnings of $32.43 per share. This is a 189.81 percent increase over earnings of $11.19 per share from the same period last year. The company reported $18.18 million in sales this quarter. This is a 9.69 percent increase over sales of $16.57 million the same period last year.

DJCO

Daily Journal Q2 EPS $32.43 Up From $11.19 YoY, Sales $18.18M Up From $16.57M YoY

Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) reported quarterly losses of $(3.71) per share. This is a 9.95 percent increase over losses of $(4.12) per share from the same period last year. The company reported $1.83 million in sales this quarter. This is a 206.87 percent increase over sales of $597.00 thousand the same period last year.

BLNE

Beeline Holdings Q1 EPS $(3.71) Up From $(4.12) YoY, Sales $1.83M Up From $597.00K YoY

Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) reported third-quarter financial results for fiscal 2025 after the market close on Tuesday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/n45529278/palo-alto-networks-reports-fiscal-third-quarter-2025-financial-results">cybersecurity company&#8217;s report</a>.
Q3 Earnings: Palo Alto reported third-quarter revenue of $2.29 billion, beating the&nbsp;<a href="http://benzinga.com/quote/PANW/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $2.28 billion. The company reported third-quarter adjusted earnings of 80 cents per share, beating analyst estimates of 77 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 15% year-over-year and remaining performance obligations grew 19% year-over-year to $13.5 billion. The cybersecurity company said next-generation security annual recurring revenue increased 34% year-over-year to $5.1 billion.
Palo Alto ended the quarter with approximately $2.38 billion in cash and cash equivalents.
&#8220;In&nbsp;Q3, we continued to make progress on our platformization strategy and achieved an important milestone in crossing&nbsp;$5 billion&nbsp;in Next-Gen Security ARR,&#8221; said&nbsp;Nikesh Arora, chairman and CEO of Palo Alto Networks. &#8220;Our scale and platform breadth makes us a leading consolidator of choice in cybersecurity.&#8221;
Guidance:&nbsp;Palo Alto expects fiscal fourth-quarter revenue to be in the range of $2.49 billion to $2.51 billion versus estimates of $2.5 billion. The company expects fourth-quarter adjusted earnings to be between 87 cents and 89 cents per share versus estimates of 86 cents per share.
Palo Alto also raised its full-year 2025 guidance. The company now expects full-year revenue of $9.17 billion to $9.19 billion, up from prior guidance of $9.14 billion to $9.19 billion. The company now anticipates full-year adjusted earnings of $3.26 to $3.28 per share, up from prior guidance of $3.18 to $3.24 per share, per&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. Analysts are forecasting full-year revenue of $9.17 billion and full-year adjusted earnings of $3.22 per share.
Palo Alto executives will further discuss the company&#8217;s quarterly performance on a conference call with investors and analysts at 4:30 p.m. ET.
PANW Price Action: <a href="https://www.benzinga.com/quote/PANW" target="_blank" rel="noreferrer noopener">Palo Alto shares</a> were up approximately 6.5% year-to-date heading into the report. The stock was down 3.81% after hours, trading at $187.09 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45526658/palo-alto-networks-is-a-top-ai-driven-cybersecurity-play-analyst">Palo Alto Networks Is A Top AI-Driven Cybersecurity Play: Analyst</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45501031/crowdstrike-announces-integration-in-nvidia-enterprise-ai-factory">CrowdStrike Announces Integration In Nvidia Enterprise AI Factory</a></li>
</ul>
Photo: Shutterstock.

Guidance

PANW

Palo Alto Reports Q3 Earnings, Raises FY25 Guidance, Shares Slide

Dividends

Carter's Cuts Quarterly Dividend From $0.80 To $0.25 Per Share

Commodities

API Weekly Crude Stock: 2.499M Barrel Build vs 1.850M Barrel Draw Est.

The trading activity of members of Congress has<a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank"> drawn increased attention</a> from retail traders. Some disclosed trades resulted in huge profits, potential conflicts of interest, and red flags.
One new member of Congress found out that trading stocks while in office might not be as easy as everyone thinks.
What Happened: Members of Congress are currently able to buy and sell stocks and options as long as they disclose within 45 days, a practice that<a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act"> the P.E.L.O.S.I. Act</a> looks to end if passed by Congress.
While some members of Congress like Marjorie Taylor Greene (R-Ga.) have<a href="https://www.benzinga.com/25/05/45527616/marjorie-taylor-greene-goes-shopping-for-tesla-netflix-unitedhealth-stock-here-are-the-latest-19-stocks-bought"> disclosed hundreds of trades</a> in 2025, Rep. John McGuire (R-Va.) is new to the game.
The Congressman who was sworn into office in January 2025 has made only one stock transaction according to the <a href="https://www.benzinga.com/gov-trades/members/john-mcguire">Benzinga Government Trades</a> page.
On April 10, McGuire purchased between $1,000 and $15,000 in UnitedHealth Group stock, one of the largest health insurance companies in the United States.
The purchase drew attention because McGuire serves on the Subcommittee on Health Care and Financial Services, a unit of the House Committee on Oversight and Accountability.
However, the timing of the trade likely couldn't have gotten much worse for McGuire, who bought the stock before <a href="https://www.benzinga.com/25/05/45494155/unitedhealth-stock-is-rising-monday-whats-going-on">quarterly financial results</a> that saw the company pull guidance and announce its CEO Andrew Witty was stepping down.
The Wall Street Journal also reported that the Justice Department was<a href="https://www.benzinga.com/general/health-care/25/05/45426769/unitedhealth-stock-plunges-over-8-in-after-hours-trading-as-doj-criminal-probe-adds-to-turmoil-after-ceo-shake-up"> investigating the company</a> for potential Medicare fraud. The health insurance company said it hasn't been notified of any investigation.
UnitedHealth Group shares traded between $580.00 and $601.88 on April 10 when McGuire made his purchase. Today, the stock trades at $321.50 and has fallen between 46.6% and 44.6% since April 10.
Assuming McGuire bought the full $15,000 value of UnitedHealth Group in his disclosure, the position would be worth $8,010 to $8,310 today.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45449720/speaker-johnson-backs-congressional-stock-trading-ban-ruined-by-a-few-bad-actors">Speaker Johnson Backs Congressional Stock Trading Ban: Ruined By &#8216;A Few Bad Actors&#8217;</a>
Why It's Important: McGuire's trade could mark a new era in which members of Congress lose money instead of making large profits on their stock and options activities.
In 2024, many members of Congress outperformed the S&amp;P 500. Former Speaker of the House Nancy Pelosi has often been the top-followed member of Congress for trading activity, with her husband Paul Pelosi often buying in-the-money options on large technology stocks.
Sen.&nbsp;Josh Hawley&nbsp;(R-Mo.) has reintroduced legislation that would ban members of Congress from trading or holding individual stocks.
The bill is known as the Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act, based on the first letter of each of the main words. The name targets Pelosi.
Hawley's bill is being reintroduced as President&nbsp;Donald Trump&nbsp;<a href="https://time.com/7280114/donald-trump-2025-interview-transcript/" target="_blank" rel="noreferrer noopener">said&nbsp;</a>he would support such a ban.
"Well, I watched Nancy Pelosi get rich through insider information, and I would be okay with it. If they send it to me, I would do it," Trump told TIME.
Trump said he would sign the ban if the bill passes Congress.
While Pelosi makes headlines for her trades, it's important to remember that<a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noreferrer noopener"> </a><a href="https://www.benzinga.com/politics/25/04/44852406/marjorie-taylor-greene-brushes-off-stock-buying-criticism-says-portfolio-manager-bought-the-dip" target="_blank" rel="noopener">both Republican</a> and Democratic members of Congress are profiting from buying and selling stocks and options while in office. Some trades have questionable timing or are connected to committees they serve on.
In 2024, a list of the top-performing traders in Congress included six Republicans and four Democrats.
For McGuire to make the 2025 list of best-performing members of Congress, he will have to buy more stocks or hope for a huge recovery in the price of UnitedHealth Group stock.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments.&nbsp;<a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent052025" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

New Congressman's First Stock Trade Tanks 45% After Betting On UnitedHealth Before Fallout

Northrop Grumman Increases Quarterly Dividend From $2.06 To $2.31/Share

XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.38 by 2.63 percent. This is a 5.41 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $741.93 million which missed the analyst consensus estimate of $755.03 million by 1.73 percent. This is a 9.39 percent decrease over sales of $818.79 million the same period last year.

Earnings Beats

XP Q1 EPS $0.39 Beats $0.38 Estimate, Sales $741.93M Miss $755.03M Estimate

Press Releases

Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation

Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology

Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment

SAGALIUM RESPONDS TO COMPETITOR'S FALSE AND MISLEADING PRESS RELEASE

Biotech

Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications

Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells

Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences  and Enzolytics, Inc. Execute Three Year Agreement

Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator

ENZC

Enzolytics

Comments

Enzolytics

Enzolytics (ENZC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL